Navigation Links
NIH awards National Jewish Health $31 million to lead study of infections associated with eczema

The National Institute of Allergy and Infections Disease has awarded a five-year $31 million contract to National Jewish Health, which is leading a consortium of academic medical centers seeking to better understand skin infections associated with atopic dermatitis. The researchers will focus on antibiotic-resistant staphylococcus aureus (MRSA) infections and widespread viral infections of the skin, both of which are more prevalent among atopic dermatitis patients.

"MRSA is a significant public health threat that needs to be contained," said principal investigator Donald Leung, MD, PhD, Professor of Allergy and Clinical Immunology at National Jewish Health. "We want to find out why these patients are susceptible to staph infections, particularly MRSA, and learn how we can prevent them from developing and spreading to others."

Atopic dermatitis, also known as eczema, is the most common skin disease in the general population, affecting approximately 20 percent of children and two percent of adults in the United States. It is a chronic disease characterized by repeated bouts of dry, itchy, irritated skin, which can make life miserable. Patients from around the country come to National Jewish Health for treatment of their severe atopic dermatitis.

Atopic dermatitis patients are particularly prone to skin infections. Sixty to 90 percent of patients have some staph organisms on their skin, and 30 percent are prone to overt infections, which can cause cracked and oozing lesions on their skin.

Because of their frequent staph infections, and possibly because of repeated antibiotic use to fight the infections, atopic dermatitis patients frequently develop MRSA infections. Although MRSA patients are isolated at National Jewish Health and other hospitals, these patients commonly have contact with friends and family outside the healthcare setting, and could be a source of infections to a wider population.

MRSA infections have emerged in recent years as a significant health problem. They are more difficult to treat, because the staph organisms are resistant to penicillin and several other first-line antibiotics. While they often cause disease no more severe than do non-resistant strains, they can cause severe disease and even death.

Researchers in the Atopic Dermatitis Research Network (ADRN), will seek to better understand why atopic dermatitis patients are susceptible to staph and other bacterial and viral infections. They will evaluate atopic dermatitis patients' genes, innate and adaptive immune responses and skin barrier to identify factors that make them susceptible to these infections. The researchers also plan to conduct a clinical trial to see if vitamin D can help reduce or prevent staph colonization and infection.

Researchers will be recruiting large numbers of atopic dermatitis patients to take part in clinical studies over the next five years. If you are interested in learning more about the Atopic Dermatitis Research Network, please call 1-888-413-5852.

Staph infections, however, are not the only potentially hazardous infections associated with atopic dermatitis. Atopic dermatitis patients are also susceptible to herpes virus infections, called eczema herpeticum, and a hazardous, potentially deadly side effect of smallpox vaccinations, eczema vaccinatum, which occurs when the vaccinia virus currently used for the smallpox vaccine, replicates uncontrollably and circulates through the entire body.

The ADRN research consortium is building on a previous five-year contract, which created the Atopic Dermatitis Vaccinia Network and identified several factors related to patients' susceptibility to eczema vaccinatum.

The Atopic Dermatitis Research Network will include researchers from National Jewish Health, Emory University, Boston Children's Hospital, Johns Hopkins University, University of Rochester, Oregon Health and Sciences University, La Jolla Institute for Allergy & Immunology, University of California Los Angeles, University of California San Diego, and University of Minnesota.


Contact: William Allstetter
National Jewish Health

Related biology news :

1. NIH awards Rice $1.7M for cartilage-regeneration research
2. International AIDS Society announces inaugural recipients of innovative HIV research awards
3. The Samuel Waxman Cancer Research Foundation awards $1.54 million in research grants for 2010-2011
4. Touch Bionics announced as a winner in the Seventh Annual International Business Awards
5. Damon Runyon Cancer Research Foundation awards prestigious fellowships to 18 top young scientists
6. PNNL scientists win 4 R&D 100 awards for environment, biology, security technologies
7. DOE awards UC San Diego consortium $9 million for algal biofuels research
8. 12 women scientists announced as winners of Elsevier Foundation TWOWS Awards
9. NSERC awards $3 million for UdeM and Polytechnique training programs
10. USPTO Awards Key Patent to ADF Solutions for Digital Forensics
11. AMIA Members Manage HITECH Stimulus Grant Awards
Post Your Comments:
(Date:10/29/2015)... 29, 2015 Today, LifeBEAM , ... with 2XU, a global leader in technical performance ... hat with advanced bio-sensing technology. The hat will ... monitor key biometrics to improve overall training performance. ... two companies will bring together the most advanced technology, ...
(Date:10/26/2015)... India , October 26, 2015 ... --> adds ... 2015 to 2021 as well as ... 2015-2019 research reports to its collection ... . --> ...
(Date:10/23/2015)... GOLETA, California , October 23, 2015 ... Instruments (SMI) announce a mobile plug and play integration ... interactive real-world tasks SensoMotoric Instruments (SMI) ... established wearable solutions for eye tracking and physiological data ... with SMI Eye Tracking Glasses 2w and ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... Studies reveal the differences in ... pave the way for more effective treatment for one of ...   --> --> Gum ... in cats, yet relatively little was understood about the bacteria ... been conducted by researchers from the WALTHAM Centre for Pet ...
(Date:11/25/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: AEZ) ... remain fundamentally strong and highlights the following developments: ... DSMB recommendation to continue the ZoptEC Phase 3 ... final interim efficacy and safety data , ... with heavily pretreated castration- and Taxane-resistant prostate cancer ...
(Date:11/25/2015)... Oregon , November 25, 2015 ... Market Research Report is a professional and in-depth ... industry.      (Logo: ) ... overview of the industry including definitions, classifications, applications ... is provided for the international markets including development ...
(Date:11/24/2015)... ... , ... The United States Golf Association (USGA) today announced Dr. Bruce Clarke, ... annually since 1961, the USGA Green Section Award recognizes an individual’s distinguished service to ... Clarke, of Iselin, N.J., is an extension specialist of turfgrass pathology in the department ...
Breaking Biology Technology: